SMT201600090B - Composizioni monovalenti per il legame a cd28 e metodi di utilizzo - Google Patents

Composizioni monovalenti per il legame a cd28 e metodi di utilizzo

Info

Publication number: SMT201600090B
Authority: SM; San Marino
Prior art keywords: monoval; bond; compositions; methods; monoval compositions
Prior art date: 2008-07-18

Application number

SM201600090T

Other languages

English (en)

Inventor

Murray Mckinnon

Steven G Nadler

Suzanne J Suchard

Brendan Classon

Steve Holmes

Olga Ignatovich

Christopher Plummer

Steve Grant

Original Assignee

Bristol Myers Squibb Co

Domantis Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-18

Filing date

2016-03-29

Publication date

2016-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600090(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-03-29 Application filed by Bristol Myers Squibb Co, Domantis Ltd filed Critical Bristol Myers Squibb Co

2016-04-29 Publication of SMT201600090B publication Critical patent/SMT201600090B/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)

SM201600090T 2008-07-18 2016-03-29 Composizioni monovalenti per il legame a cd28 e metodi di utilizzo SMT201600090B (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8207808P	2008-07-18	2008-07-18
US16212109P	2009-03-20	2009-03-20
PCT/US2009/050985 WO2010009391A1 (en)	2008-07-18	2009-07-17	Compositions monovalent for cd28 binding and methods of use

Publications (1)

Publication Number	Publication Date
SMT201600090B true SMT201600090B (it)	2016-04-29

Family

ID=41226147

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SM20190367T SMT201900367T1 (it)	2008-07-18	2009-07-17	Composizioni monovalenti per il legame a cd28 e metodi di utilizzo
SM201600090T SMT201600090B (it)	2008-07-18	2016-03-29	Composizioni monovalenti per il legame a cd28 e metodi di utilizzo

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SM20190367T SMT201900367T1 (it)	2008-07-18	2009-07-17	Composizioni monovalenti per il legame a cd28 e metodi di utilizzo

Country Status (29)

Country	Link
US (6)	US8168759B2 (it)
EP (2)	EP2700651B1 (it)
JP (3)	JP5675608B2 (it)
KR (2)	KR101791372B1 (it)
CN (2)	CN102159590A (it)
AR (1)	AR072571A1 (it)
AU (1)	AU2009270726B2 (it)
CA (1)	CA2731220C (it)
CL (2)	CL2011000117A1 (it)
CO (1)	CO6341641A2 (it)
CY (1)	CY1121796T1 (it)
DK (2)	DK2700651T3 (it)
EA (1)	EA024585B1 (it)
ES (2)	ES2562629T3 (it)
HR (2)	HRP20160329T1 (it)
HU (2)	HUE045249T2 (it)
IL (2)	IL210413A (it)
LT (1)	LT2700651T (it)
ME (1)	ME02396B (it)
MX (1)	MX2011000501A (it)
NZ (1)	NZ590343A (it)
PE (2)	PE20110385A1 (it)
PL (2)	PL2700651T3 (it)
PT (2)	PT2321352E (it)
RS (2)	RS58904B1 (it)
SI (2)	SI2700651T1 (it)
SM (2)	SMT201900367T1 (it)
TW (2)	TWI450725B (it)
WO (1)	WO2010009391A1 (it)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3613767A1 (en)	2005-05-18	2020-02-26	Ablynx N.V.	Improved nanobodiestm against tumor cecrosis factor-alpha
US20110097339A1 (en) *	2008-07-18	2011-04-28	Domantis Limited	Compositions monovalent for CD28 binding and methods of use
AR072571A1 (es) *	2008-07-18	2010-09-08	Bristol Myers Squibb Co	Composiciones monovalentes para union a cd28 y procedimientos de uso
PL2401373T3 (pl) *	2009-02-25	2014-02-28	Nextera As	Prezentacja fagowa pix niezależna od sekwencji sygnalnej
FR2951176A1 (fr) *	2009-10-09	2011-04-15	Tcl Pharma	Ligands monovalents du recepteur cd28 humain
EP2361935A1 (en) *	2010-02-18	2011-08-31	TcL Pharma	Anti-CD28 humanized antibodies
ES2896149T3 (es)	2010-02-18	2022-02-24	Ose Immunotherapeutics	Anticuerpos humanizados anti-CD28
US9000130B2 (en) *	2010-06-08	2015-04-07	Genentech, Inc.	Cysteine engineered antibodies and conjugates
JP5768022B2 (ja) *	2012-03-19	2015-08-26	株式会社東芝	メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法
WO2014120916A1 (en)	2013-02-01	2014-08-07	Bristol-Myers Squibb Company	Pegylated domain antibodies monovalent for cd28 binding and methods of use
KR102344170B1 (ko) *	2013-12-27	2021-12-27	추가이 세이야쿠 가부시키가이샤	등전점이 낮은 항체의 정제방법
EP3119809A1 (en) *	2014-03-19	2017-01-25	Bristol-Myers Squibb Company	Methods of treating transplant rejection using a domain antibody directed against cd40l
MX2017003123A (es)	2014-09-12	2017-05-12	Genentech Inc	Anticuerpos y conjugados modificados geneticamente con cisteina.
BR112017006520A2 (pt)	2014-09-30	2017-12-19	Bristol Myers Squibb Co	métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
US20190086405A1 (en)	2016-03-16	2019-03-21	Bristol-Myers Squibb Company	Methods of diagnosing and treating lupus
EP4252629A3 (en)	2016-12-07	2023-12-27	Biora Therapeutics, Inc.	Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en)	2017-03-30	2023-06-07	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
TW202515920A (zh)	2017-04-11	2025-04-16	美商因荷布瑞克斯生物科學公司	具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
AU2019234183B2 (en)	2018-03-15	2025-12-18	Biond Biologics Ltd.	Methods and compositions for decreasing soluble immune receptor CD28
CA3096123A1 (en)	2018-04-11	2019-10-17	Inhibrx, Inc.	Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
US20210251994A1 (en)	2018-06-15	2021-08-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
CA3104783A1 (en) *	2018-06-22	2019-12-26	Junten Bio Co., Ltd.	Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
WO2020014143A1 (en) *	2018-07-08	2020-01-16	Specifica Inc.	Antibody libraries with maximized antibody developability characteristics
CA3105891A1 (en)	2018-07-24	2020-01-30	Inhibrx, Inc.	Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US12385913B2 (en)	2018-08-03	2025-08-12	Bristol-Myers Squibb Company	Methods for detecting anti-drug antibodies
US20220249814A1 (en)	2018-11-19	2022-08-11	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
BR112021018205A2 (pt)	2019-03-14	2021-12-28	Biond Biologics Ltd	Pequenos agentes bloqueadores de liberação.
MA55805A (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	Métodes de modulation de l'activité immunitaire
ES2821599A1 (es) *	2019-10-24	2021-04-26	Univ Del Pais Vasco / Euskal Herriko Unibertsitatea	Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
CA3160216A1 (en) *	2019-12-02	2021-06-10	Motti HAKIM	Use of mmp inhibition
EP4309722A3 (en)	2019-12-13	2024-08-07	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4076434A1 (en)	2019-12-17	2022-10-26	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4097129A1 (en) *	2020-01-29	2022-12-07	Inhibrx, Inc.	Cd28 single domain antibodies and multivalent and multispecific constructs thereof
CN116096906A (zh)	2020-06-29	2023-05-09	旗舰创业创新五公司	工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
EP4192884A4 (en) *	2020-08-04	2025-04-09	Exelixis, Inc.	PD-L1-BINDING AGENTS AND USES THEREOF
JP2024512669A (ja)	2021-03-31	2024-03-19	フラグシップパイオニアリングイノベーションズブイ，インコーポレーテッド	タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
CA3224374A1 (en)	2021-06-29	2023-01-05	Flagship Pioneering Innovations V, Inc.	Immune cells engineered to promote thanotransmission and uses thereof
US20240279335A1 (en) *	2021-09-06	2024-08-22	Biond Biologics Ltd.	Cd28 shedding blocking agents
WO2023215799A1 (en) *	2022-05-04	2023-11-09	Janux Therapeutics, Inc.	Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
WO2023215498A2 (en) *	2022-05-05	2023-11-09	Modernatx, Inc.	Compositions and methods for cd28 antagonism
WO2023215560A1 (en)	2022-05-05	2023-11-09	Atoosa Corporation	Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
EP4572772A1 (en)	2022-08-17	2025-06-25	Capstan Therapeutics, Inc.	Conditioning for in vivo immune cell engineering
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
KR20250075711A (ko)	2022-10-06	2025-05-28	비카라 테라퓨틱스 인크.	다중특이적 단백질 및 관련 방법
WO2024151687A1 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
EP4688856A1 (en)	2023-04-03	2026-02-11	Regeneron Pharmaceuticals, Inc.	Methods of improving transplant survival using il-2 receptor gamma chain antibodies
US12311033B2 (en)	2023-05-31	2025-05-27	Capstan Therapeutics, Inc.	Lipid nanoparticle formulations and compositions
WO2025076127A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en)	2023-10-05	2025-04-10	Capstan Therapeutics, Inc.	Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en)	2024-02-22	2025-08-28	Capstan Therapeutics, Inc.	Immune engineering amplification
WO2025217452A1 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en)	2024-04-11	2025-10-16	Capstan Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4839295A (en)	1984-06-08	1989-06-13	Pierce Chemical Company	Measurement of protein using bicinchoninic acid
US5977307A (en)	1989-09-07	1999-11-02	Alkermes, Inc.	Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
CA2046830C (en)	1990-07-19	1999-12-14	Patrick P. Deluca	Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
ATE420178T1 (de)	1992-08-21	2009-01-15	Univ Bruxelles	Immunoglobuline ohne leichtkette
US6005079A (en)	1992-08-21	1999-12-21	Vrije Universiteit Brussels	Immunoglobulins devoid of light chains
US5922545A (en)	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
SE9400088D0 (sv)	1994-01-14	1994-01-14	Kabi Pharmacia Ab	Bacterial receptor structures
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
GB9416721D0 (en)	1994-08-18	1994-10-12	Short Brothers Plc	A bias yarn assembly forming device
JP4979843B2 (ja)	1995-03-10	2012-07-18	ロッシュディアグノスティクスゲゼルシャフトミットベシュレンクテルハフツング	微粒子の形のポリペプチド含有投薬形
DK1143006T3 (da)	1995-08-18	2008-07-14	Morphosys Ip Gmbh	Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
EP0988321A2 (en)	1997-06-20	2000-03-29	Innogenetics N.V.	B7-binding molecules for treating immune diseases
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
ATE281155T1 (de)	1998-04-20	2004-11-15	Genzyme Corp	Medikamentöse verabreichung von proteinen aus polymergemischen
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
WO2000069907A1 (en)	1999-05-14	2000-11-23	Medical Research Council	Protein scaffold and its use to multimerise monomeric polypeptides
US20020006403A1 (en) *	1999-12-14	2002-01-17	Xue-Zhong Yu	CD28-specific antibody compositions for use in methods of immunosuppression
JP4066166B2 (ja) *	2000-12-26	2008-03-26	アンスティテュナシオナルドラサントエドラルシュルシェメディカル（アンセルム）	抗−ｃｄ２８抗体
US7531168B2 (en)	2001-02-16	2009-05-12	Genetics Institute Llc	Method for downmodulating immune response in type I diabetes
US20080095774A1 (en) *	2001-02-16	2008-04-24	Wyeth	Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US20050089932A1 (en)	2001-04-26	2005-04-28	Avidia Research Institute	Novel proteins with targeted binding
US20030157561A1 (en)	2001-11-19	2003-08-21	Kolkman Joost A.	Combinatorial libraries of monomer domains
DE60237282D1 (de)	2001-06-28	2010-09-23	Domantis Ltd	Doppelspezifischer ligand und dessen verwendung
AU2002319544B2 (en)	2001-08-10	2008-07-10	Aberdeen University	Antigen binding domains from fish
AU2002328742A1 (en)	2001-10-05	2003-04-22	Cangene Corporation	Phagemid display system
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
DE10156482A1 (de) *	2001-11-12	2003-05-28	Gundram Jung	Bispezifisches Antikörper-Molekül
EP1600459A3 (en)	2002-06-28	2005-12-07	Domantis Limited	Ligand
JP2006520584A (ja)	2002-11-08	2006-09-14	アブリンクスエン．ヴェー．	安定化単一ドメイン抗体
CA2511910A1 (en)	2002-12-27	2004-07-15	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CA2522586C (en)	2003-05-31	2017-02-21	Micromet Ag	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
EP1675878A2 (en)	2003-10-24	2006-07-05	Avidia, Inc.	Ldl receptor class a and egf domain monomers and multimers
CN100376599C (zh)	2004-04-01	2008-03-26	北京安波特基因工程技术有限公司	基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
UA94213C2 (ru) *	2004-09-17	2011-04-26	Домантис Лимитед	Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
GB0614093D0 (en)	2006-07-14	2006-08-23	Bae Systems Plc	Deployable antenna system
AU2007331672A1 (en) *	2006-12-15	2008-06-19	Ablynx N.V.	Amino acid sequences that modulate the interaction between cells of the immune system
AR072571A1 (es) *	2008-07-18	2010-09-08	Bristol Myers Squibb Co	Composiciones monovalentes para union a cd28 y procedimientos de uso
US9120873B2 (en)	2008-08-21	2015-09-01	Octapharma Ag	Recombinantly produced human factor VIII and IX
EP3119809A1 (en) *	2014-03-19	2017-01-25	Bristol-Myers Squibb Company	Methods of treating transplant rejection using a domain antibody directed against cd40l
BR112017006520A2 (pt) *	2014-09-30	2017-12-19	Bristol Myers Squibb Co	métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28

2009
- 2009-07-17 AR ARP090102734A patent/AR072571A1/es active IP Right Grant
- 2009-07-17 MX MX2011000501A patent/MX2011000501A/es active IP Right Grant
- 2009-07-17 DK DK13185422.6T patent/DK2700651T3/da active
- 2009-07-17 KR KR1020167025702A patent/KR101791372B1/ko not_active Expired - Fee Related
- 2009-07-17 CA CA2731220A patent/CA2731220C/en not_active Expired - Fee Related
- 2009-07-17 EP EP13185422.6A patent/EP2700651B1/en active Active
- 2009-07-17 DK DK09790582.2T patent/DK2321352T3/en active
- 2009-07-17 JP JP2011518935A patent/JP5675608B2/ja not_active Expired - Fee Related
- 2009-07-17 NZ NZ590343A patent/NZ590343A/xx unknown
- 2009-07-17 SM SM20190367T patent/SMT201900367T1/it unknown
- 2009-07-17 RS RS20190631A patent/RS58904B1/sr unknown
- 2009-07-17 RS RS20160200A patent/RS54675B1/sr unknown
- 2009-07-17 PE PE2011000053A patent/PE20110385A1/es active IP Right Grant
- 2009-07-17 EP EP09790582.2A patent/EP2321352B1/en active Active
- 2009-07-17 TW TW098124305A patent/TWI450725B/zh not_active IP Right Cessation
- 2009-07-17 SI SI200931964T patent/SI2700651T1/sl unknown
- 2009-07-17 ME MEP-2016-76A patent/ME02396B/me unknown
- 2009-07-17 HU HUE13185422A patent/HUE045249T2/hu unknown
- 2009-07-17 ES ES09790582.2T patent/ES2562629T3/es active Active
- 2009-07-17 SI SI200931383T patent/SI2321352T1/sl unknown
- 2009-07-17 US US12/505,166 patent/US8168759B2/en active Active
- 2009-07-17 WO PCT/US2009/050985 patent/WO2010009391A1/en not_active Ceased
- 2009-07-17 PT PT97905822T patent/PT2321352E/pt unknown
- 2009-07-17 PL PL13185422T patent/PL2700651T3/pl unknown
- 2009-07-17 CN CN2009801358711A patent/CN102159590A/zh active Pending
- 2009-07-17 AU AU2009270726A patent/AU2009270726B2/en not_active Ceased
- 2009-07-17 PL PL09790582T patent/PL2321352T3/pl unknown
- 2009-07-17 EA EA201100239A patent/EA024585B1/ru not_active IP Right Cessation
- 2009-07-17 HR HRP20160329TT patent/HRP20160329T1/hr unknown
- 2009-07-17 ES ES13185422T patent/ES2730727T3/es active Active
- 2009-07-17 KR KR1020117003660A patent/KR101660057B1/ko active Active
- 2009-07-17 LT LTEP13185422.6T patent/LT2700651T/lt unknown
- 2009-07-17 CN CN201610344002.1A patent/CN105936648B/zh active Active
- 2009-07-17 PT PT13185422T patent/PT2700651T/pt unknown
- 2009-07-17 TW TW101147598A patent/TW201336510A/zh unknown
- 2009-07-17 HU HUE09790582A patent/HUE029982T2/en unknown
- 2009-07-17 PE PE2014000192A patent/PE20140852A1/es not_active Application Discontinuation
2010
- 2010-12-30 IL IL210413A patent/IL210413A/en active IP Right Grant
2011
- 2011-01-18 CL CL2011000117A patent/CL2011000117A1/es unknown
- 2011-02-15 CO CO11017973A patent/CO6341641A2/es active IP Right Grant
2012
- 2012-03-09 US US13/415,914 patent/US9085629B2/en active Active
- 2012-03-09 US US13/416,033 patent/US8454959B2/en not_active Expired - Fee Related
- 2012-08-31 CL CL2012002428A patent/CL2012002428A1/es unknown
2014
- 2014-12-24 JP JP2014261305A patent/JP5876134B2/ja not_active Expired - Fee Related
2015
- 2015-06-16 US US14/740,709 patent/US9908937B2/en active Active
2016
- 2016-01-20 JP JP2016009024A patent/JP6058833B2/ja not_active Expired - Fee Related
- 2016-03-29 SM SM201600090T patent/SMT201600090B/it unknown
2017
- 2017-03-21 IL IL251320A patent/IL251320B/en active IP Right Grant
2018
- 2018-01-12 US US15/870,121 patent/US10919965B2/en active Active
2019
- 2019-05-28 HR HRP20190966TT patent/HRP20190966T1/hr unknown
- 2019-07-09 CY CY20191100722T patent/CY1121796T1/el unknown
2020
- 2020-11-02 US US17/086,565 patent/US12012452B2/en active Active

Also Published As

Publication number	Publication date
PT2700651T (pt)	2019-06-19
EP2321352B1 (en)	2016-01-06
HUE045249T2 (hu)	2019-12-30
AU2009270726A1 (en)	2010-01-21
HK1155178A1 (zh)	2012-05-11
DK2700651T3 (da)	2019-07-22
US8454959B2 (en)	2013-06-04
US20210047414A1 (en)	2021-02-18
JP5675608B2 (ja)	2015-02-25
KR20160113322A (ko)	2016-09-28
EP2700651B1 (en)	2019-04-10
PL2321352T3 (pl)	2016-06-30
US10919965B2 (en)	2021-02-16
SI2700651T1 (sl)	2019-08-30
JP5876134B2 (ja)	2016-03-02
WO2010009391A1 (en)	2010-01-21
US9908937B2 (en)	2018-03-06
US20130109846A1 (en)	2013-05-02
JP2015120695A (ja)	2015-07-02
IL210413A0 (en)	2011-03-31
LT2700651T (lt)	2019-06-25
NZ590343A (en)	2012-10-26
PE20110385A1 (es)	2011-06-22
EP2700651A1 (en)	2014-02-26
RS54675B1 (sr)	2016-08-31
TWI450725B (zh)	2014-09-01
CY1121796T1 (el)	2020-07-31
JP6058833B2 (ja)	2017-01-11
PT2321352E (pt)	2016-03-18
SI2321352T1 (sl)	2016-04-29
AR072571A1 (es)	2010-09-08
CN105936648B (zh)	2020-06-16
CN105936648A (zh)	2016-09-14
AU2009270726B2 (en)	2015-07-09
ME02396B (me)	2016-08-31
IL210413A (en)	2017-04-30
IL251320A0 (en)	2017-05-29
JP2011528551A (ja)	2011-11-24
TW201006494A (en)	2010-02-16
EA024585B1 (ru)	2016-10-31
CN102159590A (zh)	2011-08-17
EP2321352A1 (en)	2011-05-18
US12012452B2 (en)	2024-06-18
US9085629B2 (en)	2015-07-21
IL251320B (en)	2019-01-31
KR20110041527A (ko)	2011-04-21
KR101791372B1 (ko)	2017-10-27
HUE029982T2 (en)	2017-04-28
US20180142023A1 (en)	2018-05-24
ES2730727T3 (es)	2019-11-12
TW201336510A (zh)	2013-09-16
CO6341641A2 (es)	2011-11-21
HRP20160329T1 (hr)	2016-04-22
EA201100239A1 (ru)	2011-10-31
HRP20190966T1 (hr)	2019-07-26
CA2731220C (en)	2017-10-10
US20100028354A1 (en)	2010-02-04
CL2012002428A1 (es)	2013-01-11
RS58904B1 (sr)	2019-08-30
PE20140852A1 (es)	2014-07-14
US8168759B2 (en)	2012-05-01
US20120201814A1 (en)	2012-08-09
US20150299321A1 (en)	2015-10-22
SMT201900367T1 (it)	2019-09-09
CL2011000117A1 (es)	2011-06-17
ES2562629T3 (es)	2016-03-07
JP2016063830A (ja)	2016-04-28
DK2321352T3 (en)	2016-04-04
CA2731220A1 (en)	2010-01-21
KR101660057B1 (ko)	2016-09-26
PL2700651T3 (pl)	2019-09-30
MX2011000501A (es)	2011-05-23

Publication	Publication Date	Title
SMT201600090B (it)	2016-04-29	Composizioni monovalenti per il legame a cd28 e metodi di utilizzo
EP2280916A4 (en)	2014-07-23	HYDROCHLORFLUOROLEFINZUSAMMENSETZUNGEN
BRPI0913806A2 (pt)	2015-10-20	"composição"
SMT201500282B (it)	2016-01-08	Strumento per lavorare il terreno
EP2500932A4 (en)	2015-10-28	ADHESIVE COMPOSITION
EP2417196A4 (en)	2013-08-07	SILENCING COMPOSITIONS
IL211147A0 (en)	2011-04-28	1h-benzimidazole-5-carboxamides as anti-inflammatory agents
DK2634231T3 (da)	2022-09-19	Sammensætninger
BRPI1013748A2 (pt)	2016-04-05	"compostos de vinil-indazolila"
ME01423B (me)	2013-12-20	Fungicidni sastavi
BRPI0924929A2 (pt)	2015-07-07	"unidade de transdutor"
EP2263545A4 (en)	2011-05-04	sonographer
PT2424374T (pt)	2018-04-23	Composições de limpeza e métodos para utilização das mesmas
BRPI0914533A2 (pt)	2015-12-15	"métodos"
BRPI0922181A2 (pt)	2016-11-01	partículas de anti-corrosivo
BR112012004593A2 (pt)	2017-05-23	"método"
BRPI0907078A2 (pt)	2015-07-07	"artigo laminado"
FR2955590B1 (fr)	2012-03-23	Compositions de nettoyage a base d'hydrochlorofluoroolefine
EP2318306A4 (en)	2012-09-12	NANOCOMPOSITES
EP2346489A4 (en)	2015-01-07	CLEANING COMPOSITIONS
BRPI1012055A2 (pt)	2016-05-17	"piperidinas substituídas"
FI20085905L (fi)	2010-03-26	Laitteisto pölyn sitomiseksi käytettävän veden määrän säätämiseksi
DK2170292T3 (da)	2014-04-07	Atazanavirholdige sammensætninger i tabletform
FR2965705B1 (fr)	2015-01-30	Compositions d'edulcorants
DK2468819T3 (da)	2014-10-06	Kobberholdige polyester-polyamidsammensætninger